Publication Date:
2012-09-22
Description:
Background: Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated withincreased morbidity and mortality. Studies regarding the status of MBD treatment indeveloping countries, especially in Chinese dialysis patients are extremely limited. Methods: A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD)patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium(Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targetswas compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3and DOPPS 4. Factors associated with hyperphosphatemia were examined. Results: Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%,39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI)defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statisticallyhigher (P 〈 0.05) in the HD patients compared with those of PD patients, which was(6.3 +/- 2.1) mg/dL vs. (5.7 +/- 2.0) mg/dL and (9.3 +/- 1.1) mg/dL vs. (9.2 +/- 1.1) mg/dL,respectively. Serum iPTH level were statistically higher in the PD patients compared withthose of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P(37.6% vs. 49.8% vs. 54.5%, P 〈 0.01), Ca (38.6% vs. 50.4% vs. 56.0%, P 〈 0.01) and iPTH(26.5% vs. 31.4% vs. 32.1%, P 〈 0.01) were lower among HD patients, compared with thedata from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus levelabove 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patternsand region of residency were independently associated with hyperphosphatemia. Conclusions: Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue ofhyperphosphatemia is prominent and needs further attention.
Electronic ISSN:
1471-2369
Topics:
Medicine
Permalink
